{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T17:57:49Z","timestamp":1761674269877,"version":"3.37.3"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,4,27]],"date-time":"2018-04-27T00:00:00Z","timestamp":1524787200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010289","name":"Princess Margaret Hospital Foundation","doi-asserted-by":"crossref","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100010289","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Mesothelioma Research Foundation","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}]},{"name":"Swiss National Science Foundation (SNF) Sinergia","award":["CRSII3 #147697"],"award-info":[{"award-number":["CRSII3 #147697"]}]},{"DOI":"10.13039\/100001755","name":"Mesothelioma Applied Research Foundation","doi-asserted-by":"crossref","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100001755","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-4354-1","type":"journal-article","created":{"date-parts":[[2018,4,27]],"date-time":"2018-04-27T02:20:38Z","timestamp":1524795638000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Putative cancer stem cells may be the key target to inhibit cancer cell repopulation between the intervals of chemoradiation in murine mesothelioma"],"prefix":"10.1186","volume":"18","author":[{"given":"Licun","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter","family":"Blum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Qi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihong","family":"Yun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laszlo","family":"Pecze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikihiro","family":"Kohno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei-Lin","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yidan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Felley-Bosco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beat","family":"Schwaller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"de Perrot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,4,27]]},"reference":[{"issue":"9","key":"4354_CR1","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.annepidem.2011.05.010","volume":"21","author":"MS Kanarek","year":"2011","unstructured":"Kanarek MS. Mesothelioma from chrysotile asbestos: update. Ann Epidemiol. 2011;21(9):688\u201397.","journal-title":"Ann Epidemiol"},{"issue":"15","key":"4354_CR2","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1056\/NEJMra050152","volume":"353","author":"BW Robinson","year":"2005","unstructured":"Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med. 2005;353(15):1591\u2013603.","journal-title":"N Engl J Med"},{"issue":"14","key":"4354_CR3","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636\u201344.","journal-title":"J Clin Oncol"},{"issue":"4","key":"4354_CR4","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/j.athoracsur.2007.11.065","volume":"85","author":"M de Perrot","year":"2008","unstructured":"de Perrot M, et al. Risk factors for major complications after extrapleural pneumonectomy for malignant pleural mesothelioma. Ann Thorac Surg. 2008;85(4):1206\u201310.","journal-title":"Ann Thorac Surg"},{"issue":"1","key":"4354_CR5","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jtcvs.2006.06.044","volume":"133","author":"M de Perrot","year":"2007","unstructured":"de Perrot M, et al. Impact of lymph node metastasis on outcome after extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2007;133(1):111\u20136.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"9","key":"4354_CR6","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1200\/JCO.2008.17.5604","volume":"27","author":"M de Perrot","year":"2009","unstructured":"de Perrot M, et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol. 2009;27(9):1413\u20138.","journal-title":"J Clin Oncol"},{"issue":"3","key":"4354_CR7","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.lungcan.2008.01.013","volume":"61","author":"K Ribi","year":"2008","unstructured":"Ribi K, et al. Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changes. Lung Cancer. 2008;61(3):398\u2013404.","journal-title":"Lung Cancer"},{"issue":"3","key":"4354_CR8","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/JTO.0000000000000078","volume":"9","author":"BC Cho","year":"2014","unstructured":"Cho BC, et al. A feasibility study evaluating surgery for mesothelioma after radiation therapy: the \"SMART\" approach for resectable malignant pleural mesothelioma. J Thorac Oncol. 2014;9(3):397\u2013402.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"4354_CR9","doi-asserted-by":"publisher","first-page":"956","DOI":"10.4049\/jimmunol.0900437","volume":"185","author":"M Anraku","year":"2010","unstructured":"Anraku M, et al. Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignant mesothelioma. J Immunol. 2010;185(2):956\u201366.","journal-title":"J Immunol"},{"issue":"9","key":"4354_CR10","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1097\/JTO.0b013e3182208ee0","volume":"6","author":"L Wu","year":"2011","unstructured":"Wu L, et al. Tumor cell repopulation between cycles of chemotherapy is inhibited by regulatory T-cell depletion in a murine mesothelioma model. J Thorac Oncol. 2011;6(9):1578\u201386.","journal-title":"J Thorac Oncol"},{"issue":"8","key":"4354_CR11","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1158\/1535-7163.MCT-11-1014","volume":"11","author":"L Wu","year":"2012","unstructured":"Wu L, et al. CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma. Mol Cancer Ther. 2012;11(8):1809\u201319.","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"4354_CR12","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1097\/CJI.0b013e3182a801f2","volume":"36","author":"T Tagawa","year":"2013","unstructured":"Tagawa T, et al. Antitumor impact of interferon-gamma producing CD1d-restricted NKT cells in murine malignant mesothelioma. J Immunother. 2013;36(8):391\u20139.","journal-title":"J Immunother"},{"issue":"12","key":"4354_CR13","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s00262-014-1597-9","volume":"63","author":"L Wu","year":"2014","unstructured":"Wu L, et al. Activation of CD1d-restricted natural killer T cells can inhibit cancer cell proliferation during chemotherapy by promoting the immune responses in murine mesothelioma. Cancer Immunol Immunother. 2014;63(12):1285\u201396.","journal-title":"Cancer Immunol Immunother"},{"issue":"14","key":"4354_CR14","doi-asserted-by":"crossref","first-page":"12468","DOI":"10.18632\/oncotarget.3487","volume":"6","author":"L Wu","year":"2015","unstructured":"Wu L, et al. Targeting the inhibitory receptor CTLA-4 on T cells increased abscopal effects in murine mesothelioma model. Oncotarget. 2015;6(14):12468\u201380.","journal-title":"Oncotarget"},{"issue":"12","key":"4354_CR15","first-page":"4614","volume":"9","author":"W Licun","year":"2003","unstructured":"Licun W, Tannock IF. Selective estrogen receptor modulators as inhibitors of repopulation of human breast cancer cell lines after chemotherapy. Clin Cancer Res. 2003;9(12):4614\u20138.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"4354_CR16","first-page":"2134","volume":"63","author":"L Wu","year":"2003","unstructured":"Wu L, Tannock IF. Repopulation in murine breast tumors during and after sequential treatments with cyclophosphamide and 5-fluorouracil. Cancer Res. 2003;63(9):2134\u20138.","journal-title":"Cancer Res"},{"issue":"17","key":"4354_CR17","doi-asserted-by":"publisher","first-page":"5389","DOI":"10.1158\/1078-0432.CCR-08-3007","volume":"15","author":"AS Fung","year":"2009","unstructured":"Fung AS, Wu L, Tannock IF. Concurrent and sequential administration of chemotherapy and the mammalian target of rapamycin inhibitor temsirolimus in human cancer cells and xenografts. Clin Cancer Res. 2009;15(17):5389\u201395.","journal-title":"Clin Cancer Res"},{"issue":"22","key":"4354_CR18","doi-asserted-by":"publisher","first-page":"8195","DOI":"10.1158\/1078-0432.CCR-05-1258","volume":"11","author":"L Wu","year":"2005","unstructured":"Wu L, Tannock IF. Effect of the selective estrogen receptor modulator arzoxifene on repopulation of hormone-responsive breast cancer xenografts between courses of chemotherapy. Clin Cancer Res. 2005;11(22):8195\u2013200.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"4354_CR19","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1158\/0008-5472.CAN-04-3137","volume":"65","author":"L Wu","year":"2005","unstructured":"Wu L, Birle DC, Tannock IF. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res. 2005;65(7):2825\u201331.","journal-title":"Cancer Res"},{"issue":"6","key":"4354_CR20","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/j.1365-3083.2010.02464.x","volume":"72","author":"AO Hovden","year":"2010","unstructured":"Hovden AO, Appel S. The first dendritic cell-based therapeutic cancer vaccine is approved by the FDA. Scand J Immunol. 2010;72(6):554.","journal-title":"Scand J Immunol"},{"issue":"1","key":"4354_CR21","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.stem.2014.10.020","volume":"16","author":"SL Prashad","year":"2015","unstructured":"Prashad SL, et al. GPI-80 defines self-renewal ability in hematopoietic stem cells during human development. Cell Stem Cell. 2015;16(1):80\u20137.","journal-title":"Cell Stem Cell"},{"issue":"5","key":"4354_CR22","doi-asserted-by":"publisher","first-page":"e0119549","DOI":"10.1371\/journal.pone.0119549","volume":"10","author":"EA Pasdar","year":"2015","unstructured":"Pasdar EA, et al. Characterisation of mesothelioma-initiating cells and their susceptibility to anti-cancer agents. PLoS One. 2015;10(5):e0119549.","journal-title":"PLoS One"},{"key":"4354_CR23","doi-asserted-by":"crossref","unstructured":"Dotse E, Bian Y. Isolation of colorectal cancer stem-like cells. Cytotechnology. 2014;68(4):609\u2013619.","DOI":"10.1007\/s10616-014-9806-0"},{"issue":"12","key":"4354_CR24","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1038\/nprot.2009.201","volume":"4","author":"A Hotta","year":"2009","unstructured":"Hotta A, et al. EOS lentiviral vector selection system for human induced pluripotent stem cells. Nat Protoc. 2009;4(12):1828\u201344.","journal-title":"Nat Protoc"},{"issue":"4","key":"4354_CR25","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.stemcr.2017.02.005","volume":"8","author":"W Blum","year":"2017","unstructured":"Blum W, et al. Stem cell factor-based identification and functional properties of in vitro-selected subpopulations of malignant mesothelioma cells. Stem Cell Reports. 2017;8(4):1005\u201317.","journal-title":"Stem Cell Reports"},{"issue":"1","key":"4354_CR26","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1002\/stem.1542","volume":"32","author":"A Shahryari","year":"2014","unstructured":"Shahryari A, et al. Two novel splice variants of SOX2OT, SOX2OT-S1, and SOX2OT-S2 are coupregulated with SOX2 and OCT4 in esophageal squamous cell carcinoma. Stem Cells. 2014;32(1):126\u201334.","journal-title":"Stem Cells"},{"issue":"7","key":"4354_CR27","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1007\/s11626-015-9885-z","volume":"51","author":"W Blum","year":"2015","unstructured":"Blum W, et al. Establishment of immortalized murine mesothelial cells and a novel mesothelioma cell line. In Vitro Cell Dev Biol Anim. 2015;51(7):714\u201321.","journal-title":"In Vitro Cell Dev Biol Anim"},{"key":"4354_CR28","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1186\/s13014-015-0575-5","volume":"10","author":"C Thieke","year":"2015","unstructured":"Thieke C, et al. Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity-modulated radiotherapy. Radiat Oncol. 2015;10:267.","journal-title":"Radiat Oncol"},{"issue":"2","key":"4354_CR29","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.jtcvs.2015.09.129","volume":"151","author":"M de Perrot","year":"2016","unstructured":"de Perrot M, et al. Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2016;151(2):468\u201373.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"4","key":"4354_CR30","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1158\/1078-0432.CCR-16-0844","volume":"23","author":"L Wu","year":"2017","unstructured":"Wu L, et al. Patient-derived xenograft establishment from human malignant pleural mesothelioma. Clin Cancer Res. 2017;23(4):1060\u20137.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"4354_CR31","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1517\/14712598.2015.1116515","volume":"15","author":"A Guazzelli","year":"2015","unstructured":"Guazzelli A, et al. Tremelimumab for the treatment of malignant mesothelioma. Expert Opin Biol Ther. 2015;15(12):1819\u201329.","journal-title":"Expert Opin Biol Ther"},{"key":"4354_CR32","doi-asserted-by":"publisher","unstructured":"A Potential Immune Therapy for Mesothelioma. Cancer Discov. 2015;5(7):OF14. https:\/\/doi.org\/10.1158\/2159-8290.CD-NB2015-067 . Epub 2015 May 8. PMID: 25956959","DOI":"10.1158\/2159-8290.CD-NB2015-067"},{"key":"4354_CR33","doi-asserted-by":"crossref","unstructured":"De La Maza L, Wu M, Wu L, Yun H, Zhao Y, Cattral M, McCart A, Cho BJ, de Perrot M. In Situ Vaccination after Accelerated Hypofractionated Radiation and Surgery in a Mesothelioma Mouse Model. Clin Cancer Res. 2017;23(18):5502\u20135513.","DOI":"10.1158\/1078-0432.CCR-17-0438"},{"issue":"7533","key":"4354_CR34","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/nature14075","volume":"517","author":"IF Tannock","year":"2015","unstructured":"Tannock IF. Cancer: resistance through repopulation. Nature. 2015;517(7533):152\u20133.","journal-title":"Nature"},{"issue":"9","key":"4354_CR35","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1158\/1078-0432.CCR-14-2298","volume":"21","author":"JK Saggar","year":"2015","unstructured":"Saggar JK, Tannock IF. Chemotherapy rescues hypoxic tumor cells and induces their Reoxygenation and repopulation-an effect that is inhibited by the hypoxia-activated prodrug TH-302. Clin Cancer Res. 2015;21(9):2107\u201314.","journal-title":"Clin Cancer Res"},{"key":"4354_CR36","doi-asserted-by":"crossref","unstructured":"Zhao Q, et al. Prognostic value of the expression of cancer stem cell-related markers CD133 and CD44 in hepatocellular carcinoma: from patients to patient-derived tumor xenograft models. Oncotarget. 2016;7(30):47431\u201347443.","DOI":"10.18632\/oncotarget.10164"},{"issue":"7604","key":"4354_CR37","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nature17997","volume":"533","author":"F Zhou","year":"2016","unstructured":"Zhou F, et al. Tracing haematopoietic stem cell formation at single-cell resolution. Nature. 2016;533(7604):487\u201392.","journal-title":"Nature"},{"issue":"10","key":"4354_CR38","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1002\/stem.1418","volume":"31","author":"H Shigeishi","year":"2013","unstructured":"Shigeishi H, et al. Maintenance of stem cell self-renewal in head and neck cancers requires actions of GSK3beta influenced by CD44 and RHAMM. Stem Cells. 2013;31(10):2073\u201383.","journal-title":"Stem Cells"},{"issue":"7117","key":"4354_CR39","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/nature05284","volume":"444","author":"J Wang","year":"2006","unstructured":"Wang J, et al. A protein interaction network for pluripotency of embryonic stem cells. Nature. 2006;444(7117):364\u20138.","journal-title":"Nature"},{"issue":"6","key":"4354_CR40","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.cell.2005.08.020","volume":"122","author":"LA Boyer","year":"2005","unstructured":"Boyer LA, et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell. 2005;122(6):947\u201356.","journal-title":"Cell"},{"issue":"7239","key":"4354_CR41","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/nature07863","volume":"458","author":"K Woltjen","year":"2009","unstructured":"Woltjen K, et al. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature. 2009;458(7239):766\u201370.","journal-title":"Nature"},{"issue":"2","key":"4354_CR42","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.scr.2014.05.006","volume":"13","author":"DA Ovchinnikov","year":"2014","unstructured":"Ovchinnikov DA, et al. Transgenic human ES and iPS reporter cell lines for identification and selection of pluripotent stem cells in vitro. Stem Cell Res. 2014;13(2):251\u201361.","journal-title":"Stem Cell Res"},{"issue":"4","key":"4354_CR43","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1159\/000443090","volume":"38","author":"V Shinde","year":"2016","unstructured":"Shinde V, et al. Simulated microgravity modulates differentiation processes of embryonic stem cells. Cell Physiol Biochem. 2016;38(4):1483\u201399.","journal-title":"Cell Physiol Biochem"},{"issue":"5","key":"4354_CR44","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.ccr.2008.03.005","volume":"13","author":"W Chen","year":"2008","unstructured":"Chen W, et al. Malignant transformation initiated by Mll-AF9: gene dosage and critical target cells. Cancer Cell. 2008;13(5):432\u201340.","journal-title":"Cancer Cell"},{"issue":"42","key":"4354_CR45","doi-asserted-by":"publisher","first-page":"17414","DOI":"10.1073\/pnas.1108945108","volume":"108","author":"W Kratky","year":"2011","unstructured":"Kratky W, et al. Direct activation of antigen-presenting cells is required for CD8+ T-cell priming and tumor vaccination. Proc Natl Acad Sci U S A. 2011;108(42):17414\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"4354_CR46","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1172\/JCI68395","volume":"123","author":"BM Carreno","year":"2013","unstructured":"Carreno BM, et al. IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity. J Clin Invest. 2013;123(8):3383\u201394.","journal-title":"J Clin Invest"},{"issue":"8","key":"4354_CR47","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1093\/jnci\/87.8.581","volume":"87","author":"EE Voest","year":"1995","unstructured":"Voest EE, et al. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst. 1995;87(8):581\u20136.","journal-title":"J Natl Cancer Inst"},{"key":"4354_CR48","first-page":"323","volume":"8","author":"ST Nguyen","year":"2015","unstructured":"Nguyen ST, et al. Targeting specificity of dendritic cells on breast cancer stem cells: in vitro and in vivo evaluations. Onco Targets Ther. 2015;8:323\u201334.","journal-title":"Onco Targets Ther"},{"issue":"3","key":"4354_CR49","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.stem.2017.01.009","volume":"20","author":"AG Kotini","year":"2017","unstructured":"Kotini AG, et al. Stage-specific human induced pluripotent stem cells map the progression of myeloid transformation to transplantable leukemia. Cell Stem Cell. 2017;20(3):315\u201328. e7","journal-title":"Cell Stem Cell"},{"issue":"6","key":"4354_CR50","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1038\/leu.2016.35","volume":"30","author":"RC Lynn","year":"2016","unstructured":"Lynn RC, et al. High-affinity FRbeta-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity. Leukemia. 2016;30(6):1355\u201364.","journal-title":"Leukemia"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4354-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-4354-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4354-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T09:29:49Z","timestamp":1604222989000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-4354-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,27]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4354"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-4354-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"type":"electronic","value":"1471-2407"}],"subject":[],"published":{"date-parts":[[2018,4,27]]},"assertion":[{"value":"15 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Animal Use Protocol (AUP# 3399) was approved by the Animal Resources Centre of University Health Network (UHN), Toronto, Canada.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read and approved the manuscript to be published by BMC Cancer journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"471"}}